Search Result

Results for "

N-methyl-D-aspartate receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) Adrenergic Receptor (1) Apoptosis (2) Calcium Channel (16) Cholinesterase (ChE) (2) Cytochrome P450 (1) Drug Metabolite (3) Endogenous Metabolite (27) ERK (2) GABA Receptor (1) GlyT (5) Histamine Receptor (1) iGluR (74) Isotope-Labeled Compounds (13) mAChR (6) MMP (1) nAChR (1) Opioid Receptor (3) PACAP Receptor (2) Potassium Channel (3) Prostaglandin Receptor (1) Serotonin Transporter (1) TRP Channel (2) Virus Protease (3)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Endocrinology (3) Infection (3) Inflammation/Immunology (9) Metabolic Disease (18) Neurological Disease (61)

By Targets:

17β-HSD (1)

Adrenergic Receptor (1)

Apoptosis (2)

Calcium Channel (16)

Cholinesterase (ChE) (2)

Cytochrome P450 (1)

Drug Metabolite (3)

Endogenous Metabolite (27)

ERK (2)

GABA Receptor (1)

GlyT (5)

Histamine Receptor (1)

iGluR (74)

Isotope-Labeled Compounds (13)

mAChR (6)

MMP (1)

nAChR (1)

Opioid Receptor (3)

PACAP Receptor (2)

Potassium Channel (3)

Prostaglandin Receptor (1)

Serotonin Transporter (1)

TRP Channel (2)

Virus Protease (3)

By Research Areas:

Cancer (6)

Cardiovascular Disease (1)

Endocrinology (3)

Infection (3)

Inflammation/Immunology (9)

Metabolic Disease (18)

Neurological Disease (61)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100807

Quinolinic acid 4 Publications Verification	Endogenous Metabolite iGluR	Neurological Disease Inflammation/Immunology
Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) *receptor* agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-100807S

Quinolinic acid-d3	Endogenous Metabolite iGluR	Neurological Disease Inflammation/Immunology
Quinolinic acid-d₃ is the deuterium labeled Quinolinic acid. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction[1][2].

HY-100807R

Quinolinic acid (Standard) 4 Publications Verification	Endogenous Metabolite iGluR	Neurological Disease Inflammation/Immunology
Quinolinic acid (Standard) is the analytical standard of Quinolinic acid. This product is intended for research and analytical applications. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) *receptor* agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-N2311

Ibotenic acid 5+ Cited Publications (RS)-Ibotenic acid; DL-Ibotenic acid	iGluR	Neurological Disease
Ibotenic acid has agonist activity at both the N-methyl-D-aspartate (NMDA) and trans-ACPD or metabolotropic quisqualate (Q_m) receptor sites.

HY-100667

UBP608	iGluR	Neurological Disease
UBP608 is a potent N-Methyl-D-aspartate receptors (NMDARs) negative allosteric modulator. UBP608 has the potential for the research of neurological disorders .

HY-123655

Fenazinel dihydrochloride	Others	Neurological Disease
Fenazinel dihydrochloride, an N-methyl-D-aspartate (NMDA) receptor antagonist, shows promise as a potential treatment for ischemic stroke.

HY-100807S1

Quinolinic acid-13C7	Isotope-Labeled Compounds	Others
Quinolinic acid- ¹³C₇is the ¹³C labeledQuinolinic acid(HY-100807) . Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) *receptor* agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-16728

Rapastinel GLYX-13	iGluR	Neurological Disease
Rapastinel (GLYX-13) is an N-methyl-D-aspartate receptor (NMDAR) modulator that has characteristics of a glycine site partial agonist.

HY-101353

LY 235959 (-)-LY 235959	iGluR	Neurological Disease
LY 235959 is a competitive N-methyl-D-aspartate (NMDA)-receptor antagonist. LY 235959 potentiates the anticonvulsant action of antiepileptics .

HY-114550

LY339434	iGluR	Neurological Disease
LY339434 is a potent and selective agonist for the hydrochloride receptor GluR5. LY339434 affects the rapid death of neurons through n-methyl-D-aspartate (NMDA) receptors .

HY-109164

Zelquistinel AGN-241751; GATE-251	iGluR	Neurological Disease
Zelquistinel (AGN-241751) is a **N-methyl-D-aspartate (NMDA) receptor** partial agonist used for the research of depression, anxiety and other related psychiatric disorders .

HY-107702

CGP 37849	iGluR	Neurological Disease
CGP 37849 is a potent, competitive and orally active N-methyl-D-aspartate (NMDA) receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects .

HY-B0591

Memantine 5 Publications Verification	iGluR	Neurological Disease
Memantine is an orally active, noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine can be used for the research of moderate-to-severe Alzheimer's disease (AD) .

HY-17001

Flupirtine Maleate 1 Publications Verification	Potassium Channel iGluR	Neurological Disease
Flupirtine Maleate is a?brain?penetrant, and orally bioavailable, non-opioid and centrally acting analgesic agent. Flupirtine Maleate is an indirect N-methyl-D-aspartate receptor (NMDAR) antagonist. Neuroprotective properties .

HY-138973

Neramexane	iGluR
Neramexane is an oral **N-methyl-D-aspartate (NMDA) receptor** antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.

HY-W835175

Neramexane hydrochloride	iGluR
Neramexane hydrochloride is an oral **N-methyl-D-aspartate (NMDA) receptor** antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.

HY-138973A

Neramexane mesylate	iGluR nAChR	Neurological Disease
Neramexane mesylate is an α9α10 cholinergic nicotinic receptors and **N-methyl-D-aspartate receptors*(NMDA*) antagonist. Neramexane mesylate can improve moderate to severe tinnitus, and also shows neuroprotective effects .

HY-15084A

(-)-Dizocilpine maleate (-)-MK-801 maleate	iGluR	Neurological Disease
(-)-Dizocilpine maleate ((-)-MK-801 maleate) is a less active (-)-enantiomer of Dizocilpine. (-)-Dizocilpine maleate is a selective and non-competitive **N-methyl-D-aspartate (NMDA) receptor antagonist with a K_i** of 211.7 nM. (-)-Dizocilpine maleate has antidepressant effects .

HY-106441A

Rislenemdaz MK-0657; CERC-301	iGluR	Neurological Disease
Rislenemdaz (CERC-301) is an orally bioavailable and selective N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B) antagonist with K_i and IC₅₀ of 8.1 nM and 3.6 nM, respectively.

HY-45609

L-Cysteine S-sulfate sodium hydrate	iGluR Endogenous Metabolite	Neurological Disease
L-Cysteine S-sulfate sodium hydrate is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptors agonist. L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry operations .

HY-15786

SGE-201	Others	Neurological Disease
SGE-201 is an allosteric modulator of N-methyl-D-aspartate receptors (NMDARs), demonstrating significant neuroprotective effects by enhancing NMDAR-mediated responses while differing in action among various blockers in neuronal networks.

HY-113084

L-Cysteine S-sulfate	iGluR Endogenous Metabolite	Neurological Disease
L-Cysteine S-sulfate is a potent **N-methyl-d-aspartate (NMDA) glutamatergic receptor** agonist. L-Cysteine S-sulfate is the substrate for cystine lyase, and can be used in mass spectrometry operations .

HY-100787

L-Cysteine S-sulfate sodium	iGluR Endogenous Metabolite	Neurological Disease
L-Cysteine S-sulfate sodium is a potent **N-methyl-d-aspartate (NMDA) glutamatergic receptors** agonist. L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry operations .

HY-107694

(Rac)-Dizocilpine (Rac)-MK-801	Others	Others
(Rac)-Dizocilpine ((Rac)-MK-801) is the racemate of Dizocilpine (HY-15084B). Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive **N-methyl-D-aspartate (NMDA) receptor** antagonist .

HY-P7060

NT 13 TPPT	iGluR	Neurological Disease
NT 13 (TPPT) is a tetrapeptide having the amino acid sequence L-threonyl-L-prolyl-L-prolyl-L-threonine amide. NT 13 is a partial N-methyl-D-aspartate receptor (NMDAR) agonist used in the study of depression, anxiety, and other related diseases.

HY-105627A

Profadol hydrochloride CI-572 hydrochloride	GABA Receptor iGluR	Cardiovascular Disease
Profadol (CI-572) hydrochloride is a potent analgesic agent. Profadol is a *µ-opioid receptor* (MOR)** agonist. Profadol hydrochloride activates the γ-aminobutyric acid (GABA) receptors and inhibits the N-methyl-D-aspartate (NMDA) receptor. Profadol increases the mRNA and protein expression of MOR .

HY-B1487

Procyclidine hydrochloride Tricyclamol hydrochloride; (±)-Procyclidine hydrochloride	iGluR mAChR	Neurological Disease
Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .

HY-B1487A

Procyclidine Tricyclamol; (±)-Procyclidine	mAChR iGluR	Neurological Disease
Procyclidine (Tricyclamol; (±)-Procyclidine), an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .

HY-B0591S

Memantine-d3 hydrochloride	Isotope-Labeled Compounds iGluR	Neurological Disease
Memantine-d₃ (hydrochloride) is deuterium labeled Memantine. Memantine is an orally active, noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine can be used for the research of moderate-to-severe Alzheimer's disease (AD)[1][2][3].

HY-N11061

Withaphysalin D	iGluR	Neurological Disease
Withaphysalin D is a selective antagonist against the N-methyl-D-aspartate receptor (NMDAR) containing GluN2B. Withaphysalin D can be isolated from water lilies and has neuroprotective properties. Withaphysalin D is able to cross the blood-brain barrier .

HY-100807S2

Quinolinic acid-13C4,15N	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Quinolinic acid-13C4, 15N is an isotopic labeled Quinolinic acid (HY-100807). Quinolinic acid is an endogenous **N-methyl-D-aspartate (NMDA) receptor** agonist and has the potential of mediating NMDA neuronal damage and dysfunction .

HY-101037

Sarcosine 1 Publications Verification N-methylglycine; Sarcosin	Endogenous Metabolite GlyT	Cancer
Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and **N-methyl-D-aspartate (NMDA) receptor** co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-101178

L-689560	iGluR	Neurological Disease
L-689560 is a potent N-methyl-D-aspartate (NMDA) receptor antagonist at the GluN1 glycine binding site. L-689560 is widely used as a radiolabeled ligand in binding studies and used for study the roles of NMDA receptors in normal neurological processes as well as in diseases .

HY-P1293

Conantokin G	iGluR	Neurological Disease
Conantokin G, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of **N-methyl-D-aspartate (NMDA) receptors. Conantokin G inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀** of 480 nM. Conantokin G has neuroprotective properties .

HY-139048

Fluoroethylnormemantine	iGluR	Neurological Disease
Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the **N-methyl-D-aspartate (NMDA) receptor**. [ ¹⁸F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .

HY-139048A

Fluoroethylnormemantine hydrochloride	iGluR	Neurological Disease
Fluoroethylnormemantine hydrochloride, a derivative of Memantine, is an antagonist of the **N-methyl-D-aspartate (NMDA) receptor**. [ ¹⁸F]-Fluoroethylnormemantine hydrochloride can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine hydrochloride exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .

HY-107703

CGP 39551	iGluR	Neurological Disease
CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity . CGP 39551 shows measurable inhibitory activity at both L-[ ³H]-glutamate (K_i=8.4 μM) .

HY-156634

Risevistinel NYX-783	iGluR	Neurological Disease
Risevistinel (NYX-783) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .

HY-136299

Sepimostat 1 Publications Verification FUT-187 free base	iGluR	Neurological Disease
Sepimostat (FUT-187 free base) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat inhibits the Ifenprodil binding with a K_i value of 27.7 µM .

HY-136299A

Sepimostat dimethanesulfonate FUT-187	iGluR	Neurological Disease
Sepimostat dimethanesulfonate (FUT-187) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat dimethanesulfonate inhibits the Ifenprodil binding with a K_i value of 27.7 µM .

HY-109097

Otaplimastat SP-8203	MMP iGluR	Neurological Disease
Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks **N-methyl-D-aspartate (NMDA) receptor**-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury .

HY-100714

DL-AP5 Maximum Cited Publications 17 Publications Verification 2-APV; DL-2-Amino-5-phosphonovaleric acid	iGluR	Neurological Disease Inflammation/Immunology
DL-AP5 (2-APV) is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina .

HY-100714C

DL-AP5 sodium Maximum Cited Publications 17 Publications Verification 2-APV sodium; DL-2-Amino-5-phosphonovaleric acid sodium	iGluR	Neurological Disease Inflammation/Immunology
DL-AP5 (2-APV) sodium is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 sodium shows significantly antinociceptive activity. DL-AP5 sodium specifically blocks on channels in the rabbit retina .

HY-17001R

Flupirtine Maleate (Standard)	Potassium Channel iGluR	Neurological Disease
Flupirtine (Maleate) (Standard) is the analytical standard of Flupirtine (Maleate). This product is intended for research and analytical applications. Flupirtine Maleate is a brain penetrant, and orally bioavailable, non-opioid and centrally acting analgesic agent. Flupirtine Maleate is an indirect N-methyl-D-aspartate receptor (NMDAR) antagonist. Neuroprotective properties .

HY-153129

EP2 receptor antagonist-2	Prostaglandin Receptor	Endocrinology
EP2 receptor antagonist-2 (CID891729) is an antagonist of EP2 receptor. EP2 receptor antagonist-2 inhibits the EP2 receptor activation induced by PGE2. EP2 receptor antagonist-2 also suppresses lactate dehydrogenase (LDH) release induced by N-methyl-D-aspartate (NMDA) .

HY-15086

Selfotel CGS 19755	iGluR	Neurological Disease
Selfotel (CGS 19755) is a selective and competitive antagonist at N-methyl-D-aspartate (NMDA)-preferring receptor. CGS 19755 inhibits the binding of [3H]-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid to NMDA-type receptors with an IC₅₀ of 50 nM .

HY-P1293A

Conantokin G TFA	iGluR	Neurological Disease
Conantokin G TFA, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of **N-methyl-D-aspartate (NMDA) receptors. Conantokin G TFA inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀** of 480 nM. Conantokin G TFA has neuroprotective properties .

HY-156626

Nevadistinel NYX-458; NYX-3054	iGluR	Neurological Disease
Nevadistinel (NYX-458; NYX-3054) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .

HY-100714D

DL-AP5 lithium 2-APV lithium; DL-2-Amino-5-phosphonovaleric acid lithium	iGluR	Neurological Disease Inflammation/Immunology
DL-AP5 (2-APV) lithium is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 lithium shows significantly antinociceptive activity. DL-AP5 lithium specifically blocks on channels in the rabbit retina .

HY-B1487R

Procyclidine hydrochloride (Standard)	iGluR mAChR	Neurological Disease
Procyclidine (hydrochloride) (Standard) is the analytical standard of Procyclidine (hydrochloride). This product is intended for research and analytical applications. Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .

Cat. No.	Product Name	Target	Research Area

HY-P5912

GluN1(356-385)	Peptides	Neurological Disease
GluN1 (356-385) is an antigenic peptide against N-methyl-D-aspartate receptor (NMDAR) encephalitis. GluN1 (356-385) has the effect of reducing the density of surface NMDAR clusters in hippocampal neurons. GluN1 (356-385) can be used to study the pathogenesis of anti-NMDAR encephalitis .

HY-117483

Gly-Pro-Glu	Peptides	Neurological Disease
Gly-Pro-Glu is a neuroactive peptide with a potent action on acetylcholine release. Gly-Pro-Glu is the N-terminal tripeptide of insulin-like growth factor-I. Gly-Pro-Glu inhibits glutamate binds to N-methyl-D-aspartate (NMDA) receptor with an IC₅₀ value of 14.7 μM. Gly-Pro-Glu can be used for the research of neuroprotection .

HY-P5911

GluN1(359-378)	iGluR	Inflammation/Immunology
GluN1 (359-378) is an anti-N-methyl-D-aspartate receptor (NMDAR) peptide. GluN1 (359-378) can cross the blood-brain barrier. GluN1 (359-378) can be used to study anti-NMDAR encephalitis therapy targeting the immune system .

HY-113084

L-Cysteine S-sulfate	iGluR Endogenous Metabolite	Neurological Disease
L-Cysteine S-sulfate is a potent **N-methyl-d-aspartate (NMDA) glutamatergic receptor** agonist. L-Cysteine S-sulfate is the substrate for cystine lyase, and can be used in mass spectrometry operations .

HY-P7060

NT 13 TPPT	iGluR	Neurological Disease
NT 13 (TPPT) is a tetrapeptide having the amino acid sequence L-threonyl-L-prolyl-L-prolyl-L-threonine amide. NT 13 is a partial N-methyl-D-aspartate receptor (NMDAR) agonist used in the study of depression, anxiety, and other related diseases.

HY-P1293

Conantokin G	iGluR	Neurological Disease
Conantokin G, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of **N-methyl-D-aspartate (NMDA) receptors. Conantokin G inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀** of 480 nM. Conantokin G has neuroprotective properties .

HY-P1293A

Conantokin G TFA	iGluR	Neurological Disease
Conantokin G TFA, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of **N-methyl-D-aspartate (NMDA) receptors. Conantokin G TFA inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀** of 480 nM. Conantokin G TFA has neuroprotective properties .

HY-P1287

Conantokin-T	iGluR	Neurological Disease
Conantokin-T is a γ-carboxyglutamate-containing, N-methyl-D-aspartate (NMDA) antagonist peptidewith an IC₅₀ value of 2 μM. Conantokin-T inhibits NMDA receptor-mediated calcium influx in central nervous system neurons. Conantokin-T can be purified from the venom of the fish-hunting cone snail, Conus tulipa .

HY-P0221C

PACAP (1-38) free acid	PACAP Receptor	Endocrinology
PACAP (1-38) free acid is an endogenous neuropeptide. PACAP (1-38) free acid potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .

HY-P0221B

PACAP (1-38) free acid TFA	PACAP Receptor	Endocrinology
PACAP (1-38) free acid TFA is an endogenous neuropeptide. PACAP (1-38) free acid TFA potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid TFA also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-100807

Quinolinic acid 4 Publications Verification	Alkaloids Structural Classification Microorganisms Disease markers Pyridine Alkaloids Nervous System Disorder Endogenous metabolite	Endogenous Metabolite iGluR
Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) *receptor* agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-100807R

Quinolinic acid (Standard) 4 Publications Verification	Structural Classification Alkaloids Microorganisms Ketones, Aldehydes, Acids Source classification Disease markers Pyridine Alkaloids Nervous System Disorder Endogenous metabolite	Endogenous Metabolite iGluR
Quinolinic acid (Standard) is the analytical standard of Quinolinic acid. This product is intended for research and analytical applications. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) *receptor* agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-N2311

Ibotenic acid Maximum Cited Publications 7 Publications Verification (RS)-Ibotenic acid; DL-Ibotenic acid	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	iGluR
Ibotenic acid has agonist activity at both the N-methyl-D-aspartate (NMDA) and trans-ACPD or metabolotropic quisqualate (Q_m) receptor sites.

HY-45609

L-Cysteine S-sulfate sodium hydrate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	iGluR Endogenous Metabolite
L-Cysteine S-sulfate sodium hydrate is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptors agonist. L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry operations .

HY-101037

Sarcosine 1 Publications Verification N-methylglycine; Sarcosin	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Classification of Application Fields Source classification Disease markers Endocrine diseases Amino acids Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite GlyT
Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and **N-methyl-D-aspartate (NMDA) receptor** co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-113084

L-Cysteine S-sulfate	Structural Classification Natural Products Immune System Disorder Neurological Disease Classification of Application Fields Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields	iGluR Endogenous Metabolite
L-Cysteine S-sulfate is a potent **N-methyl-d-aspartate (NMDA) glutamatergic receptor** agonist. L-Cysteine S-sulfate is the substrate for cystine lyase, and can be used in mass spectrometry operations .

HY-100787

L-Cysteine S-sulfate sodium	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	iGluR Endogenous Metabolite
L-Cysteine S-sulfate sodium is a potent **N-methyl-d-aspartate (NMDA) glutamatergic receptors** agonist. L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry operations .

HY-N11061

Withaphysalin D	Structural Classification Physalis minima Linn. Source classification Plants Solanaceae Steroids	iGluR
Withaphysalin D is a selective antagonist against the N-methyl-D-aspartate receptor (NMDAR) containing GluN2B. Withaphysalin D can be isolated from water lilies and has neuroprotective properties. Withaphysalin D is able to cross the blood-brain barrier .

HY-P1293

Conantokin G	Structural Classification Natural Products Animals Source classification	iGluR
Conantokin G, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of **N-methyl-D-aspartate (NMDA) receptors. Conantokin G inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀** of 480 nM. Conantokin G has neuroprotective properties .

HY-P1293A

Conantokin G TFA	Natural Products Animals Source classification	iGluR
Conantokin G TFA, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of **N-methyl-D-aspartate (NMDA) receptors. Conantokin G TFA inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀** of 480 nM. Conantokin G TFA has neuroprotective properties .

HY-101037R

Sarcosine (Standard)	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Source classification Disease markers Endocrine diseases Amino acids Endogenous metabolite	Endogenous Metabolite GlyT
Sarcosine (Standard) is the analytical standard of Sarcosine. This product is intended for research and analytical applications. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-17387

(-)-Huperzine A 4 Publications Verification Huperzine A	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Anti-aging Terpenoids Huperziaceae Sesquiterpenes Pyridine Alkaloids Huperzia serrata Plants Disease Research Fields	Cholinesterase (ChE) Apoptosis iGluR
(-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC₅₀ of 82 nM. (-)-Huperzine A also is non-competitive antagonist of **N-methyl-D-aspartate glutamate (NMDA) receptor**. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .

HY-N0215

L-Phenylalanine 2 Publications Verification Phenylalanine	Structural Classification Microorganisms Animals Classification of Application Fields Source classification Metabolic Disease Amino acids Endogenous metabolite Disease Research Fields	Calcium Channel iGluR Endogenous Metabolite
L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca ⁺ channels antagonist with a K_i of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (K_B of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals .

HY-N0215R

L-Phenylalanine (Standard)	Structural Classification Microorganisms Animals Source classification Amino acids Endogenous metabolite	Calcium Channel iGluR Endogenous Metabolite
L-Phenylalanine (Standard) is the analytical standard of L-Phenylalanine. This product is intended for research and analytical applications. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals .

Cat. No.	Product Name	Chemical Structure

HY-100807S

Quinolinic acid-d3
Quinolinic acid-d₃ is the deuterium labeled Quinolinic acid. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction[1][2].

HY-101037S1

Sarcosine-d3

Sarcosine-d₃ is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-101037S

Sarcosine-15N

Sarcosine- ¹⁵N is the ¹⁵N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-G0021S1

N-Desmethylclozapine-d8 hydrochloride

N-Desmethylclozapine-d₈ (hydrochloride) is the deuterium labeled N-Desmethylclozapine hydrochloride. N-Desmethylclozapine hydrochloride is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine hydrochloride is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine hydrochloride is also a δ-opioid agonist[1][2][3].

HY-100807S1

Quinolinic acid-13C7
Quinolinic acid- ¹³C₇is the ¹³C labeledQuinolinic acid(HY-100807) . Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) *receptor* agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-B0591S

Memantine-d3 hydrochloride
Memantine-d₃ (hydrochloride) is deuterium labeled Memantine. Memantine is an orally active, noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine can be used for the research of moderate-to-severe Alzheimer's disease (AD)[1][2][3].

HY-100807S2

Quinolinic acid-13C4,15N
Quinolinic acid-13C4, 15N is an isotopic labeled Quinolinic acid (HY-100807). Quinolinic acid is an endogenous **N-methyl-D-aspartate (NMDA) receptor** agonist and has the potential of mediating NMDA neuronal damage and dysfunction .

HY-G0021S

N-Desmethylclozapine-d8

N-Desmethylclozapine-d₈ is the deuterium labeled N-Desmethylclozapine. N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist[1][2].

HY-N0215S6

DL-Phenylalanine-d5 hydrochloride

DL-Phenylalanine-d₅ (hydrochloride) is the deuterium labeled DL-Phenylalanine hydrochloride. L-Phenylalanine hydrochloride is an essential amino acid isolated from Escherichia coli. L-Phenylalanine hydrochloride is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine hydrochloride is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine hydrochloride is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-17387S1

(-)-Huperzine A-d4 hydrochloride

(-)-Huperzine A-d₄ hydrochloride is deuterated labeled (-)-Huperzine A (HY-17387). (-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC₅₀ of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .

HY-N0215S13

L-Phenylalanine-d1

L-Phenylalanine-d is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S3

L-Phenylalanine-d2

L-Phenylalanine-d₂ is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S2

L-Phenylalanine-13C

L-Phenylalanine- ¹³C is the ¹³C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S

L-Phenylalanine-d7

L-Phenylalanine-d₇ is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S1

L-Phenylalanine-d8

L-Phenylalanine-d₈ is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S5

L-Phenylalanine-15N

L-Phenylalanine- ¹⁵N is the ¹⁵N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S10

L-Phenylalanine-13C9

L-Phenylalanine- ¹³C₉ is the ¹³C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S12

L-Phenylalanine-d5

1 Publications Verification

L-Phenylalanine-d₅ is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S7

L-Phenylalanine-3-13C

L-Phenylalanine-3- ¹³C is the ¹³C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S8

L-Phenylalanine-13C6

L-Phenylalanine- ¹³C₆ is the ¹³C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S11

L-Phenylalanine-13C9,15N

L-Phenylalanine- ¹³C₉, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S14

L-Phenylalanine-15N,d8

L-Phenylalanine- ¹⁵N,d₈ is the deuterium and ¹⁵N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca2+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

HY-N0215S9

L-Phenylalanine-13C9,15N,d8

L-Phenylalanine- ¹³C₉, ¹⁵N,d₈ is the deuterium, ¹³C-, and 15-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

N-methyl-D-aspartate receptors

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products